Journal of Clinical Oncology
Articles in this Issue
Steroid receptor expression and overall survival in breast cancer patients with ER+ bone metastasis: A retrospective review.
1077 Background: Endocrine therapy (ET) resistance is common in estrogen receptor-positive (ER+) metastatic breast cancer (BC), where bone metastases (BME...
A patient-reported outcome measure (PROM) to capture patients' experiences with immuno-oncology therapy (IO)-induced cytokine release syndrome (CRS): The IO-induced CRS patient diary.
11129 Background: IO-inducedCRS has various signs and symptoms that impact different aspects of patients’ lives. While the frequency and severity of IO-in...
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
3001 Background: iza-bren is a first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated to a novel to...
DNA methylation biomarkers of cardiotoxicity risk in breast cancer patients treated with anthracyclines.
12021 Background: Anthracyclines are effective chemotherapeutic agents for treating breast cancer but are associated with significant risks of chemotherap...
Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).
8522 Background: In NSCLC, ctDNA analysis complements assessment of clinical efficacy and identifies molecular alterations that may be prognostic or predi...
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
TPS1120 Background: Breast radiotherapy (RT) is the standard of care for patients with early-stage breast cancer (BC) who undergo breast-conserving surger...
Access to new therapies and outcomes in Brazilian patients with metastatic non-small cell lung cancer (mNSCLC).
e23310 Background: In the last decade, different agents were incorporated to treatment of mNSCLC, from chemotherapy (CT) alone to tyrosine kinase inhibito...
Exploration of different EGFR scores and their relationship with prognosis in patients with urothelial carcinoma with squamous differentiation.
e16565 Background: EGFR-targeted ADCs have demonstrated preliminary efficacy in Urothelial carcinoma (UC). UC with squamous differentiation (UCSC) is typi...
Health care resource utilization (HCRU) and costs in insured patients with advanced lung cancer with or without clinical trial participation (CTP).
e13526 Background: Clinical trials are often recommended for cancer treatment, but CTP remains low. CTP barriers may include higher costs to the patient o...
Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study.
11513 Background: Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare sarcoma, with low sensitivity to classic chemotherapy. A previous clinical tr...
Nucleophosmin ( <i>NPM1</i> ) genomic alterations (GA) in acute myeloid leukemia (AML): A genomic landscape study.
6528 Background: NPM1 GA characterize a clinically important subset of AML cases which relapse in more than 50% of treated patients despite be...
Spatial transcriptomic analysis of the ImmunoADAPT trial: Neoadjuvant endocrine therapy combined with palbociclib and avelumab in early-stage ER-positive breast cancer.
e12624 Background: Pre-clinical studies show that CDK4/6 inhibitors can synergize with PD-(L)1 inhibitors via upregulating adaptive immune system response...
A phase Ia study to estimate the radiochemical and radiation safety of <sup>68G</sup> a-NYM005, a radiolabeled carbonic anhydrase IX PET imaging agent for diagnosing, staging, and following patients with clear cell renal cell carcinoma.
e16508 Background: 68 Ga-NYM005, a first-in-class carbonic anhydrase IX (CAIX)–binding radiolabeled small-molecule, is a quantitative PET imag...
Clinical impact of integrating polygenic risk scores with breast cancer risk assessment models: Results from the prospective multisite GENRE-2 clinical trial.
10544 Background: Incorporation of Polygenic Risk Scores (PRS) can refine traditional breast cancer risk assessment models to provide precise estimates of...
Cost-effectiveness of dose reduction of monoclonal antibodies.
e13531 Background: Monoclonal antibodies (mAbs) are being increasingly used for many diseases but can be cost prohibitive. Hematology Oncology Pharmacy As...
Timing is everything: How gen AI-driven digital platforms influence the way real-world cancer patients search for, learn about, and enroll in clinical trials.
e13635 Background: AI-driven digital platforms are essential tools for cancer patients (pts) seeking treatment (tx) options. Understanding patient behavio...
Unveiling inequities in retinoblastoma treatment: A SEER-based analysis of race, ethnicity, geography, and income (2000–2021).
e13794 Background: Retinoblastoma is a rare childhood intra-ocular malignancy. The impact of geographic and demographic variables on treatment time and op...
Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).
TPS6584 Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid disorders that occur predominantly in older patients with...
Detection of ESR1 and PIK3CA actionable mutations in breast cancer using liquid biopsy: A step toward precision medicine.
e13070 Background: The new targeted treatment options for HR+/HER2- recurrent breast cancer patients, has enhanced the value of biomarker analysis by NGS....
A phase 2 clinical trial of adjuvant ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive salivary gland cancer.
TPS6124 Background: Salivary gland carcinomas (SGCs) represent a rare, but unique group of histologically and molecularly distinct head and neck cancers....
Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span.
2632 Background: Advanced computational AI algorithms, such as ENLIGHT and DeepPT (Med 2023, Nature Cancer 2024), represen...
AI-driven design of novel PARP inhibitors.
3091 Background: Inhibitors of the Poly (ADP-ribose) polymerase (PARP) family play a role in treating HER2-negative locally advanced or metastatic breast...
Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.
6031 Background: T cell immunoglobulin and mucin domain molecule 3 (Tim-3) is an inhibitory immune checkpoint receptor that negatively regulates the immun...
Investigating the educational and practice needs of oncology pharmacists in West Africa: A case study of Nigeria.
e21021 Background: West Africa, especially Nigeria, faces a disproportionate burden of cancer incidence and mortality, along with disparities in cancer ca...
The role of LYCAT in EGFR-TKI resistance, NSCLC progression, and smoking-induced lung cancer.
e20021 Background: Non-small cell lung cancer (NSCLC) makes up 85% of lung cancer cases, often with epidermal growth factor receptor (EGFR) mutations, tar...